Managing the metabolic adverse effects of antipsychotic drugs in patients with psychosis

Australian Prescriber

Volumn 34, Issue 4, 2011, Pages 97-99

  Lambert, Tim ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Adverse effects; Obesity; Psychotic disorders

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LITHIUM; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRIACYLGLYCEROL; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZIPRASIDONE;

ARTICLE; BARIATRIC SURGERY; CARDIOVASCULAR RISK; COGNITIVE DEFECT; DIET THERAPY; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; ETHNIC DIFFERENCE; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; KINESIOTHERAPY; LIFESTYLE MODIFICATION; METABOLIC DISORDER; MORBID OBESITY; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; PHYSICAL ACTIVITY; PRESCRIPTION; PSYCHOSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 79961200886     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2011.057     Document Type: Article

References (12)

1. Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry 2007;68 Suppl:4-7.
2. De Hert M, Kalnicka D, van Winkel R, Wampers M, Hanssens L, Van Eyck D, et al. Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2006;67:1889-96.
3. John AP, Koloth R, Dragovic M, Lim SC. Prevalence of metabolic syndrome among Australians with severe mental illness. Med J Aust 2009;190:176-9.
4. Dekker MJ, Su Q, Baker C, Rutledge AC, Adeli K. Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome. Am J Physiol Endocrinol Metab 2010;299:E685-94.
5. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf 2006;29:303-19.
6. Poulin MJ, Chaput JP, Simard V, Vincent P, Beriner J, Gauthier Y, et al. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust N Z J Psychiatry 2007;41:980-9.
7. Gabriele JM, Dubbert PM, Reeves RR. Efficacy of behavioural interventions in managing atypical antipsychotic weight gain. Obes Rev 2009;10:442-55.
8. Lambert TJ, Chapman LH; Consensus Working Group. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004;181:544-8.
9. Kreyenbuhl J, Dickerson FB, Medoff DR, Brown CH, Goldberg RW, Fang L, et al. Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness. J Nerv Ment Dis 2006;194:404-10.
10. Piette JD, Heisler M, Ganoczy D, McCarthy JF, Valenstein M. Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension. Psychiatr Serv 2007;58:207-12.
11. Hamoui N, Kingsbury S, Anthone GJ, Crookes PF. Surgical treatment of morbid obesity in schizophrenic patients. Obes Surg 2004;14:349-52.
12. Strohmayer E, Via MA, Yanagisawa R. Metabolic management following bariatric surgery. Mt Sinai J Med 2010;77:431-45.